Overview
Monoclonal antibodies are an important branch of new therapeutics that address many clinical indications. LC-MS plays a critical role in advancing monoclonal antibodies from discovery to development, identifying amino acids that can undergo modifications such as deamidation, cyclization, oxidation, and disulfide bond scrambling which can adversely impact biological activity. To arrive at one or two lead candidate sequences with the fewest sequence liabilities, dozens of peptide maps and glycan profile must be generated. The Andrew+ Robot powered by OneLab Software can significantly accelerate LC-MS workflow of monoclonal antibodies, eliminating tedious steps prone to human error.